News Alert

NACHC Asks HHS to Swiftly Punish Drug Makers for 340B Pricing Denials Involving Contract Pharmacies

A letter from NACHC to HHS Secretary Xavier Becerra
NACHC urged HHS Secretary Xavier Becerra to hold drug manufacturers accountable for restricting shipments of 340B drugs to contract pharmacies.

The National Association of Community Health Centers (NACHC) strongly urged the U.S. Health and Human Services Secretary Xavier Becerra yesterday “to swiftly impose” fines on drug manufacturers that restrict shipments of 340B-purchased drugs to contract pharmacies and “hold manufacturers accountable

Read More »

News Alert

New Study Finds 340B Contract Pharmacy Growth in Affluent and White Neighborhoods, Hospitals Criticize Research

screenshot of a JAMA Health Forum research letter
340B contract pharmacy grew in affluent and White neighborhoods from 2011 to 2019 but declined in impoverished, Black, and Latino neighborhoods, a study published in JAMA Health Forum found. AHA strongly criticized the study.

340B contract pharmacy grew in affluent and White neighborhoods from 2011 to 2019 but declined in impoverished, Black, and Latino neighborhoods, raising questions about “the degree to which 340B program growth serves vulnerable communities,” according to research published this morning

Read More »

The Supreme Court Aftermath: What Comes Next in Fight Over Medicare Part B Drug Payments to 340B Hospitals?

The U.S. Supreme Court building and entrance plaza
Yesterday's U.S. Supreme Court's opinion about deep cuts in 340B hospitals’ Medicare Part B drug reimbursement ended Phase 1 of the debate. Phase 2 gets underway next month in lower federal courts in Washington, D.C., and in the pages of the Federal register.

Yesterday, the U.S. Supreme Court ruled that huge cuts in 340B hospitals’ Medicare Part B drug reimbursement in 2018 and 2019 were unlawful. It marked the end of Phase 1 of the debate over the cuts.

Phase 2 is gearing

Read More »

Bipartisan U.S. House Group Renewing Pressure on HHS to Punish Drug Makers Over 340B Pricing Denials

Headshots of U.S. House gang of six Representatives Spanberger, Axne, McKinley, Matsui, Katko, Johnson
Clockwise from top left, Reps. Abigail D. Spanberger (D-Va.), Cindy Axne (D-Iowa), David McKinley (R-W.Va.), Doris Matsui (D-Calif.), John Katko (R-N.Y.), and Dusty Johnson (R-S.D.) are urging fellow House members to sign a letter urging HHS to begin 340B enforcement actions against drug companies.

Six U.S. House members—three Democrats and three Republicans—are urging fellow representatives to sign a letter asking U.S. Health and Human Services (HHS) Department leaders “to begin enforcement actions against pharmaceutical companies that refuse to honor 340B discounts on prescription drugs.”

Read More »

NACHC Tells Merck its 340B Contract Pharmacy Policy for Health Centers Can Be Explained by “Only Greed”

Merck corporate campus outdoor sign and building
NACHC's president and CEO told her counterpart at Merck the company's decision to impose conditions on 340B on health centers, but not on other grantee covered entities, "cannot be explained by logic, only greed.”

The National Association of Community Health Centers this week strongly urged drug manufacturer Merck to eliminate “all conditions imposed on health centers to receive 340B price drugs at contract pharmacies.”

Merck’s April 28 decision to extend its restrictions on 340B pricing

Read More »

Breaking News

U.S. Supreme Court Strikes Down Medicare Part B Drug Payment Cuts for 340B Hospitals in 2018 and 2019

Statue and Corinthian capitals at the entrance to the Supreme Court building
The U.S. Supreme Court today struck down deep Medicare Part B drug reimbursement cuts for many 340B hospitals during 2018 and 2019. The decision does not affect continuation of the cuts in 2020 through this year, however.

UPDATE, June 15, 2022, 12:45 p.m. EDT—The U.S. Centers for Medicare & Medicaid Services said, “We are aware and reviewing the decision.”


The U.S. Supreme Court ruled unanimously this morning that the federal government unlawfully slashed Medicare Part

Read More »

Arizona Lawmakers Pass and Send 340B Anti-discrimination Bill to Governor

Arizona Gov. Doug Ducey headshot
Arizona lawmakers have sent Gov. Doug Ducey (R) legislation prohibiting various forms of pharmacy benefit manager discrimination against 340B covered entities.

Arizona lawmakers passed legislation last week prohibiting various forms of pharmacy benefit manager discrimination against 340B covered entities.

Gov. Doug Ducey (R) has not signaled if he will sign SB 1176, veto it, or let it become law without his

Read More »

HRSA Seeks Comments on Proposed Changes to 340B Program Forms

screenshot of HRSA Office of Pharmacy Affairs 340B welcome page
HRSA is seeking comment on plans to revise online forms covered entities must fill when they enroll in the 340B program, recertify their eligibility annually, or update information in 340B OPAIS, the federal 340B program database.

The U.S. Health Resources and Services Administration (HRSA) is seeking comment on plans to revise online forms covered entities must fill out when they enroll in the 340B program, recertify their eligibility annually, or update information in 340B OPAIS, the

Read More »

News Alert

Health Centers Ask Congress and Biden to Intervene to Protect 340B Savings from Pharma and PBM “Greed”

bar chart of health centers' 340B savings utilization
An infographic NACHC released today in conjunction with a new survey of its members. The health center association wants Congress and the Biden administration to pass laws protecting centers from drug manufacturer and PBM policies that it says threaten centers' financial viability.

The National Association of Community Health Centers urged Congress and the Biden administration this afternoon to force drug companies to ship 340B drugs to contract pharmacies unconditionally and stop pharmacy benefit managers from siphoning off health centers’ 340B savings.

NACHC

Read More »

Novartis and United Therapeutics File Briefs in Appeals Court in 340B Contract Pharmacy Lawsuits

U.S. federal appeals court Washington, D.C. building
Novartis and United Therapeutics filed briefs last night in a federal appeals court in Washington, D.C., backing their right to impose conditions on 340B sales.

Drug manufacturers Novartis and United Therapeutics (UT) last night urged a federal appeals court in Washington, D.C., to affirm a lower court’s November 2021 judgement that the 340B statute does not stop manufacturers from attaching any conditions to 340B drug

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report